

50618204 8/12/06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 21 IPC search and display fields enhanced in CA/CAplus with the  
IPC reform  
NEWS 4 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 5 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 6 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 7 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 8 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 9 JAN 30 Saved answer limit increased  
NEWS 10 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA  
NEWS 11 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 12 FEB 22 Status of current WO (PCT) information on STN  
NEWS 13 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 14 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 15 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 16 FEB 28 MEDLINE/LMEDLINE reload improves functionality  
NEWS 17 FEB 28 TOXCENTER reloaded with enhancements  
NEWS 18 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral  
property data  
NEWS 19 MAR 01 INSPEC reloaded and enhanced  
NEWS 20 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 21 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 22 MAR 22 EMBASE is now updated on a daily basis  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific

50618204 8/12/06

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:21:11 ON 01 APR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:21:19 ON 01 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 MAR 2006 HIGHEST RN 878649-01-5

DICTIONARY FILE UPDATES: 30 MAR 2006 HIGHEST RN 878649-01-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10669794.str



chain nodes :  
6 13 14 25  
ring nodes :  
1 2 3 4 5 7 8 9 10 11 12 15 16 17 18 19 20  
chain bonds :  
4-6 5-13 6-7 13-14 14-15 14-25  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17  
17-18 18-19 19-20  
exact/norm bonds :  
1-2 1-5 2-3 3-4 4-5 4-6 5-13 6-7 13-14 14-15 14-25 15-16 15-20 16-17  
17-18 18-19 19-20  
normalized bonds :  
7-8 7-12 8-9 9-10 10-11 11-12  
isolated ring systems :  
containing 1 : 7 :

G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 25:CLASS


50618204 8/12/06

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:21:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*



PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\106697941.str



chain nodes :  
6 7 8 9 20  
ring nodes :  
1 2 3 4 5 10 11 12 13 14 15  
chain bonds :  
4-6 5-8 6-7 8-9 9-10 9-20  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15  
exact/norm bonds :  
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 8-9 9-10 9-20 10-11 10-15 11-12 12-13  
13-14 14-15  
isolated ring systems :  
containing 1 : 7 :


G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:CLASS 9:CLASS 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 20:CLASS

L3 STRUCTURE UPLOADED

50618204 8/12/06

=> d  
L3 HAS NO ANSWERS  
L3 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3  
SAMPLE SEARCH INITIATED 11:26:35 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 0 TO 0  
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s l4 full  
FULL SEARCH INITIATED 11:28:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 20 ANSWERS  
SEARCH TIME: 00.00.01

L5 20 SEA SSS FUL L3

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
SINCE FILE ENTRY 172.22  
TOTAL SESSION 172.43

FILE 'CAPLUS' ENTERED AT 11:28:59 ON 01 APR 2006

50618204 8/12/06

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Apr 2006 VOL 144 ISS 15  
FILE LAST UPDATED: 31 Mar 2006 (20060331/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15


L6 2 L5

=> d ibib abs hitstr tot

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2004:29204 CAPLUS  
 DOCUMENT NUMBER: 140:303665  
 TITLE: Preparation of pyrazole amides for treating HIV infections  
 INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, David  
 Anthony; Selby, Matthew Duncan; Stupples, Paul Anthony  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029051	A1	20040408	WO 2003-1B4071	20030915
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2495338	AA	20040408	CA 2003-2495338	20030915
AU 2003263455	A1	20040419	AU 2003-263455	20030915
BR 2003014759	A	20050726	BR 2003-14759	20030915
EP 1556381	A1	20050727	EP 2003-798295	20030915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006505625	T2	20060216	JP 2005-501939	20030915
US 2005004129	A1	20050106	US 2003-669794	20030923
PRIORITY APPL. INFO.:			GB 2002-22375	A 20020926
			GB 2002-23357	A 20021008
			US 2002-433220P	P 20021213
			WO 2003-1B4071	W 20030915
OTHER SOURCE(S):	MARPAT 140:303665			
GI				

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The title compds. [I: WXY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH, or, when

X = CH, may also be N; R1 = a bond, alkylene, R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, were prepared and formulated.

Thus, reacting [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetic acid (preparation given) with 5,6,7,8-tetrahydro-[1,6]naphthyridine afforded II. The compds. I were tested for inhibition of HIV-1 reverse transcriptase enzyme (data were given for representative compds. I). The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).


IT 676994-33-SP 676994-34-6P 676994-35-7P  
 676994-36-8P 676994-38-0P 676994-39-1P  
 676994-40-4P 676994-41-5P 676994-42-6P  
 676994-43-7P 676994-44-8P 676994-45-9P  
 676994-47-1P 676994-48-2P 676994-49-3P  
 676994-50-6P 676994-51-7P 676994-52-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses)


(preparation of pyrazole amides for treating HIV infections)

RN 676994-33-5 CAPLUS  
 CN 1,6-Naphthyridine, 6-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 676994-34-6 CAPLUS  
 CN Pyrido[3,4-d]pyrimidine, 7-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 676994-35-7 CAPLUS  
 CN Pyrido[4,3-d]pyrimidine, 6-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 676994-36-8 CAPLUS  
 CN Pyrido[3,4-d]pyrimidine, 7-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro-4-methoxy- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 676994-38-0 CAPLUS  
 CN 1,6-Naphthyridine, 6-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 676994-39-1 CAPLUS  
 CN 6-Isquinolinecarbonitrile, 2-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 676994-40-4 CAPLUS  
 CN Isoquinoline, 2-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 676994-41-5 CAPLUS  
CN 1H-isoindole, 2-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 676994-42-6 CAPLUS  
CN Pyrido[4,3-d]pyrimidine, 6-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 676994-43-7 CAPLUS  
CN 1H-isoindole, 2-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 676994-48-2 CAPLUS  
CN Pyrido[3,4-d]pyrimidine, 7-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 676994-49-3 CAPLUS  
CN Isoquinoline, 2-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 676994-50-6 CAPLUS  
CN Pyrido[4,3-d]pyrimidine, 6-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 676994-44-8 CAPLUS  
CN Pyrido[4,3-d]pyrimidin-2-amine, 6-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 676994-45-9 CAPLUS  
CN 1H-isoindole, 2-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 676994-47-1 CAPLUS  
CN 1,6-Naphthyridin-2(1H)-one, 6-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 676994-51-7 CAPLUS  
CN 1,6-Naphthyridine, 6-[[4-(3-chloro-5-cyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 676994-52-8 CAPLUS  
CN Isoquinoline, 2-[[4-(3,5-dicyanophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:832763 CAPLUS  
 DOCUMENT NUMBER: 137:337884  
 TITLE: Preparation of aryloxy pyrazole derivatives as reverse transcriptase inhibitors for treating HIV  
 INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, Davis Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 306 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085860	A1	20021031	WO 2002-181234	20020404
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2443449	AA	20021031	CA 2002-2443449	20020404
EP 1377556	A1	20040107	EP 2002-708600	20020404
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300497	A	20040216	EE 2003-497	20020404
BR 2002008811	A	20040309	BR 2002-8811	20020404
CN 1514828	A	20040721	CN 2002-811625	20020404
JP 2004531535	T2	20041014	JP 2002-583387	20020404
NZ 529403	A	20050624	NZ 2002-529403	20020404
US 2003100554	A1	20030529	US 2002-118512	20020405
ZA 2003007095	A	20040910	ZA 2003-7095	20030910
BG 108244	A	20050430	BG 2003-108244	20031008
NO 2003004523	A	20031209	NO 2003-4523	20031009
US 2006020012	A1	20060126	US 2005-157340	20050620

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 137:337884  
 GI

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB This invention relates to pyrazole derivs. (shown as I; e.g. 2-Amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-4(3H)-pyrimidinone) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined below, and to processes for the preparation thereof, intermediates used in their preparation of, compds. containing them and the uses of such derivs. The compds. of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compds. of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). In tests of inhibition of HIV-1 reverse transcriptase enzyme, the claimed compds. 2-amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-4(3H)-pyrimidinone, 3,5-dimethyl-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile and 1-(3-azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole had IC50 values of 39,000, 3,200 and 248 nM, resp. In I: R1 is H, C1-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R10, -CONR5R10, R8 or R9. R2 is H, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ph, benzyl, R8 or R9; or, R1 and R2, when taken together, represent unbranched C3-C6 alkylene. R3 is H, C1-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R5, -CONR5R5, R8 or R9; R4 is Ph, naphthyl or pyridyl. Definitions of R5 and R7-R10 and addnl. specifications are given in the claims. Included are 283 claimed-compound preps. and 115 intermediate preps.

IT 473922-03-1P, 1-[[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetyl]piperidine 473922-04-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Drug candidate; preparation of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)


RN 473922-03-1 CAPLUS  
 CN Piperidine, 1-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]- (9C1) (CA INDEX NAME)

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 473922-04-2 CAPLUS  
 CN 3-Piperidinol, 1-[[4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazol-3-yl]acetyl]-, (3R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

50618204 8/12/06

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.68

183.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.50

-1.50

STN INTERNATIONAL LOGOFF AT 11:29:25 ON 01 APR 2006